Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells $2,229,600.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the transaction, the chief executive officer owned 577,133 shares of the company’s stock, valued at approximately $85,785,049.12. The trade was a 2.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, August 3rd, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00.
• On Wednesday, July 1st, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00.

Gilead Sciences Trading Down 0.2%

Shares of GILD traded down $0.31 during trading hours on Wednesday, hitting $149.61. 4,918,316 shares of the stock were exchanged, compared to its average volume of 7,003,209. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The business has a 50-day moving average of $135.17 and a 200-day moving average of $136.46. The firm has a market capitalization of $185.51 billion, a P/E ratio of -56.03 and a beta of 0.33. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. Gilead Sciences’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.01 earnings per share. On average, research analysts expect that Gilead Sciences, Inc. will post -0.47 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is currently -122.85%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC acquired a new position in Gilead Sciences during the fourth quarter worth $215,000. Sivia Capital Partners LLC lifted its holdings in shares of Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares in the last quarter. Ieq Capital LLC boosted its position in shares of Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after buying an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC boosted its position in shares of Gilead Sciences by 18.6% during the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 674 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several recent analyst reports. Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Zacks Research upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday. Morgan Stanley reduced their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research report on Monday, July 27th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research note on Wednesday, May 20th. Finally, Weiss Ratings lowered shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $158.04.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Zacks upgraded Gilead to a “Strong Buy” (Zacks Rank #1), citing improving earnings prospects. The upgrade could increase buying interest and support the shares. Gilead Upgraded to Strong Buy
• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $9.36 from $9.30, with quarterly estimates also increased slightly to $2.09 for Q1, $2.24 for Q2, $2.43 for Q3 and $2.60 for Q4. The revisions indicate modestly stronger expectations for Gilead’s future profitability.
• Positive Sentiment: FDA approval of Bixlenvo expands Gilead’s HIV portfolio with a single-tablet regimen designed to serve underserved patients. The product could provide an additional source of HIV-related revenue, although commercial adoption will determine its financial impact. Bixlenvo HIV Growth Article
• Neutral Sentiment: Erste Group Bank also raised its forecasts, lifting FY2027 EPS expectations to $9.86 from $9.57 and improving its FY2026 estimate to a loss of $0.45 per share from a loss of $0.75. These changes reinforce improving expectations but remain analyst estimates rather than reported results.
• Neutral Sentiment: GILD is trading near its 52-week high, which reflects strong recent momentum but may also limit the immediate impact of additional positive revisions. Investors may focus on whether Bixlenvo generates meaningful sales and whether projected earnings growth is achieved.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.